Cullinan Therapeutics, Inc. Common Stock (CGEM) Stock Price
CGEMStock
$12.93+47.94%52W
Market Cap$832.11M
P/E—
PEG Ratio—
Div yield—
Beta-0.01
CGEM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.80%
Price vs S&P 500 (4W)-38.11%
VGM Score55.36
CGEM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.85 | -$0.81 | +4.85%(+$0.04) | |
| Q1 2026 | -$0.84 | -$0.75 | +11.06%(+$0.09) | |
| Q4 2025 | -$0.84 | -$0.77 | +8.21%(+$0.07) | |
| Q3 2025 | -$0.89 | -$0.77 | +13.68%(+$0.12) | |
| Q2 2025 | -$0.86 | -$1.07 | -25.03%(-$0.21) |
CGEM Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.42
4.42
4.42
4.42
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
CGEMCullinan Therapeutics, Inc. Common Stock | — | — | C | — | — | — | — | $12.93 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on immunology and oncology therapies. The company develops treatments that inhibit key disease drivers or harness the immune system to eliminate diseased cells in cancer and autoimmune indications. Its pipeline leverages differentiated expertise in translational medicine and immunology to address unmet needs across multiple therapeutic areas.